This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Dyadic International (DIL) shares rose nearly 13% to $1.85 a day after the company said it restructured an agreement with research partner TNO Quality of Life. The move effectively eliminates a profit-sharing and royalty-rights arrangement related to Dyadic's fungal high-throughput screening system and also settles an outstanding debt that a Dyadic unit owed to TNO.

Shares of Celgene (CELG - Get Report) rose 4.6% to $60.12 after the Food and Drug Administration approved Revlimid for treating transfusion-dependent anemia. The company also said Sol Barer will replace John Jackson as CEO on May 1 and set plans for a 2-for-1 stock split.

CAS Medical Systems (CASM - Get Report) received clearance from the Food and Drug Administration to market its Near Infrared Spectroscopy Adult Cerebral Oximeter Monitor. The news sent shares of CAS higher by $2.09, or 31%, to $8.84. The product is a continuous, noninvasive monitor measuring absolute levels of brain tissue oxygen saturation, and the company plans to start selling it in late 2006.

Shares of Affymetrix (AFFX) surged almost 7% to $46.72 after Standard & Poor's said the company will take the place of Whole Foods in the MidCap 400. Whole Foods is being moved to the S&P 500. Volume in Affymetrix was about two-and-a-half times the normal amount for a full session.

Prospect Medical Holdings (PZZ) skyrocketed 34% to $5.75 after the company posted fourth-quarter revenue of $35.5 million, up from $35 million in the same period last year, and said net income rose to $1 million, or 13 cents a share from $908,000, or 11 cents a share, a year ago.

Get Jim Cramer's picks for 2006.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AFFX $14.01 0.14%
CELG $99.76 -1.90%
CASM $1.88 -6.00%
AAPL $92.58 -0.71%
FB $119.11 1.10%


Chart of I:DJI
DOW 17,720.91 +60.20 0.34%
S&P 500 2,056.96 +6.33 0.31%
NASDAQ 4,732.14 +15.0460 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs